drugset / Trial / NCT04181346

Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT04181346

Phase 2 Unknown 82 enrolled Faculdade de Medicina do ABC
RandomizedParallel-groupDouble-blindTreatment

Summary

phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)

Timeline

Start
2019-09-01
Primary completion
2020-02-28
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg

Indications

No indication recorded.